Bausch Health Companies vs Regeneron Pharmaceuticals
BHC and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and REGN compare
Regeneron Pharmaceuticals is the larger company, worth 31 times as much as Bausch Health Companies ($95.5B against $3.1B).
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 10.1% for Bausch Health Companies).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with −10.1% at Bausch Health Companies.
Regeneron Pharmaceuticals pays a dividend yielding 0.40%; Bausch Health Companies does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (17 against 7 for Bausch Health Companies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | REGN |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $95.5B |
| Share price | $8.20 | $927.89 |
| Change, 1 year | 39.0% | 42.1% |
| Change, 5 years | −70.7% | 51.7% |
| Beta (5Y) | 1.05 | 0.64 |
| Employees | 20K | 15K |
| StockData Score | ||
| Total score | 7 | 17 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 20.5× |
| P/S | 0.3× (better) | 5.7× |
| P/B | – | 2.9× |
| EV/EBITDA | 11.2× (better) | 16.4× |
| P/FCF | 2.1× (better) | 25.0× |
| PEG | – | 7.41 |
| FCF yield | 46.7% (better) | 4.0% |
| Fair value | $24.85 | $851.58 |
| Margin of safety | 67.0% (better) | −9.0% |
| Growth | ||
| Revenue growth (TTM) | 10.1% | 18.6% (better) |
| Revenue growth, 5Y average | 5.0% | 11.0% (better) |
| Net income growth (TTM) | −1220% | 5.2% (better) |
| EPS growth (TTM) | −1238% | 8.4% (better) |
| EPS growth, 5Y average | – | 6.3% |
| Profitability | ||
| Operating margin | 8.1% | 28.8% (better) |
| Net margin | −10.1% | 28.5% (better) |
| FCF margin | 13.2% | 22.6% (better) |
| Return on equity | – | 14.9% |
| Return on invested capital | 3.8% | 16.3% (better) |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Net debt / EBITDA | 9.20 (better) | −1.36 |
| Interest coverage | 0.5× | 104× (better) |
| Current ratio | 1.44 | 3.35 (better) |
| Altman Z-score | 0.11 | 7.64 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.40% |
| Payout ratio | – | 8.0% |
| Buyback yield | – | 2.1% |
| Shareholder yield | 0.00% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 63.4% | 89.0% |
| Held by insiders | 31.5% | 3.8% |
| Insider net buying, 12 months | $15.1M (better) | −$8.7M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 3.3% | 2.2% |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.